These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 20036435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 8. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K, Coté TR.
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [Abstract] [Full Text] [Related]

  • 9. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM.
    Drug Discov Today; 2011 Jan 05; 16(1-2):73-80. PubMed ID: 21094692
    [Abstract] [Full Text] [Related]

  • 14. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Do investors value the FDA orphan drug designation?
    Miller KL.
    Orphanet J Rare Dis; 2017 Jun 19; 12(1):114. PubMed ID: 28629392
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug repositioning for orphan diseases.
    Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG.
    Brief Bioinform; 2011 Jul 19; 12(4):346-56. PubMed ID: 21504985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.